the way to personalized medicine
BÜHLMANN Molecular
Molecular diagnostics tests are on the forefront for the diagnosis of infectious diseases, cancer, genetic disorders and pharmacogenetics. BÜHLMANN is your partner to bring the newest automated molecular diagnostics solutions into your lab.
Seegene
Founded in 2000 and based in Rockville (USA) and Seoul, Korea, Seegene, Inc. is pioneering the field of multi-pathogen testing. Seegene specializes in oligonucleotide assays and two core technologies named DPO™ (Dual Priming Oligonucleotide) and READ™ (REal Amplicon Detection), which maximize the sensitivity and specificity of PCR. These breakthrough technologies have been applied in various fields and yielded significant achievements. Seegene applies Seeplex®, Anyplex™ and Magicplex™ its breakthrough multiplexing PCR technology platforms, that enables a new standard in simultaneous multi-pathogen detection delivering maximum specificity, reproducibility and sensitivity. Seegene, Inc. obtained ISO9001 and ISO13485 certification.
Autogenomics
AutoGenomics, Inc. has developed one of the first automated microarray based multiplexing molecular diagnostic platforms that can be used to assess disease signatures with novel genomic markers in the area of infectious diseases, pharmacogenetics, cancer and genetic disorders.
With discovery of genes and their link to various disease states the INFINITI® platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the new era of personalized medicine.
EntroGen
EntroGen, Inc is a US based bio-technology company developing novel genotyping assays in the area of oncology. Their mission is to offer easy-to-use and inexpensive genotyping and mutation analysis assays to the laboratories that can be run on nearly all existing real-time PCR instruments.
Ikonisys
Ikonisys, Inc. is transforming diagnostic medicine by enabling early, accurate and non-invasive disease detection. Through a unique combination of technology and science, Ikonisys is dedicated to helping researchers and physicians realize the promise of rare cell detection to give patients the best chance of managing their disease.Most exciting, through its integration of intelligent imaging, microscopy, biology and informatics, Ikonisys is laying the foundation for detecting a single cell and identifying its molecular signals, a long-term key to maximizing patient health and wellness.
Seegene |
AutoGenomics |
| EntroGen |
Ikonisys |
Contact
Baselstr. 55
CH-4124 Schönenbuch
Switzerland
Fon: +41 61 487 12 12
Fax: +41 61 487 12 34
info@buhlmannlabs.ch
Your local distributor
Order
About us
Job opportunities
Search
News
NEW OWN CALPROTECTIN REIMBURSEMENT POSITION IN SWITZERLAND
BÜHLMANN is very proud to announce that the calprotectin determination in stool starting from January 1st 2012, has an official new position in the reimb more
New Seegene DPO Movie showing how this unique and proprietary technology is working to allow innovative multiplexing.
The unique and proprietary DPO™(Dual-Priming-Oligonucleotide) technology is the corner stone for all of the Seegene products, and it is the key to achieve more
New EntroGen BRAF test (V600E/K/D) for the detection of important mutations found in melanoma on your real-time PCR instrument.
EntroGen has a new BRAF test that detects, beside the V600E mutation, also the V600K and the V600D, which are important mutations found in melanoma. more
BÜHLMANN innovations and news at the JIB
At the JIB Congress in Paris, 8th – 10th November 2011, BÜHLMANN presents the MDx products of EntroGen and AutoGenomics as well as new developments of its more
BÜHLMANN Core | BÜHLMANN Molecular | BÜHLMANN Medical | Customer Relations | About Us |
Contact |




